Posts Tagged ‘Ozempic’

Can Novo Nordisk Dodge a Senate Subpoena on Pricing?

June 12, 2024 — Senator Bernie Sanders doesn’t want to let this go. Novo Nordisk isn’t eager to cut its thousand-dollar list price for Ozempic. Nor is it eager to face a grilling about this in the Senate. So yesterday, Sanders announced that the Senate Health, Education, Labor, and Pensions committee will vote next Tuesday on a subpoena for […]

Semaglutide Cuts Kidney Failure and Death in Diabetes

May 25, 2024 — We’ve been waiting for this. Back in October, headlines flashed the news that Novo Nordisk had stopped a big outcomes study of semaglutide and its effect on kidney failure and death. They stopped it because it had worked so well. Continuing to give a placebo to half the people in the study would have been […]

Will We Miss Ozempic on TikTok?

May 22, 2024 — In a certain way, Ozempic and TikTok were made for each other. One is the most viral social media of the moment. The other is an omnipresent sensation in medical therapy. Both of them fill a vacuum in popular culture. For TikTok, the vacuum might be boredom – though we admit that this assessment comes […]

Pressure Builds on GLP-1 Pricing, with More to Come

April 30, 2024 — Last week, the U.S. Senate launched an investigation into the high price of semaglutide, sold as Ozempic and Wegovy by Novo Nordisk. Yes, pressure on GLP-1 pricing is building and you can be confident there’s more to come. Senator Bernie Sanders chairs the Senate Committee on Health, Education, Labor, and Pensions, which is undertaking this […]

Will Policy Makers or Market Forces Lower GLP-1 Costs First?

March 28, 2024 — A new economic analysis in JAMA Network Open brings unsurprising news: manufacturing costs for GLP-1 agonists are a tiny fraction of the price for these important medicines. This is always the case for innovative prescription drugs that must recover billions of dollars of development costs in order to be profitable. The response from policy makers […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Block That Metaphor! Ozempic Orthodontia

January 18, 2024 — E.B. White is long gone from this life and Block That Metaphor! is dormant at The New Yorker. But we need them back. The Washington Post has a new and twisted metaphor about obesity treatment, casting Ozempic as something like orthodontia. Kate Cohen writes: “I always thought I’d be thin if I were rich. “I’d […]

2023: The Year Ozempic Took Over the World, for Better or Worse

December 26, 2023 — In the New Yorker, Dhruv Khullar calls 2023 “the year of Ozempic.” Then in Vox, Constance Grady puts it right up there with Barbie, calling this “the year of Ozempic bodies and Barbie Botox.” The New York Times puts it at the very top of five health lessons we learned in 2023. Most notably, Science […]

Angst About Holiday Food, Health, and Happiness

December 23, 2023 — The approach of the big holiday of Christmas often conjures thoughts about sharing meals and festive food. Many tables are overflowing with excess and with that excess comes a certain amount of angst about holiday food, health, and personal happiness. This year, we have a new twist on how to cope. Popular media is serving […]

What Became of Trends We Expected to Shape 2023?

December 11, 2023 — “Prediction is difficult, especially if it’s about the future.” Niels Bohr and Yogi Berra both get credit for this pithy bit of wisdom, but the truth is that the proverbial expression has a Danish origin and an unknown author. So now that wit and wisdom emboldens us to look back at the trends we thought […]